NCT02411136View on ClinicalTrials.gov

A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 623 in Subjects With Systemic Lupus Erythematosus

PHASE1CompletedINTERVENTIONAL

Enrollment

64

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

August 31, 2007

Study Completion Date

October 31, 2007

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG

AMG 623

Multiple doses of AMG 623 administered as subcutaneous and intravenous doses

DRUG

Placebo

Multiple doses of AMG 623 administered as subcutaneous and intravenous doses

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY